Martha E Rodriguez

USPTO Granted Patents = 25 (Patent Applications = 11)

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 8)

Average Co-Inventor Count = 11.3

ph-index = 6

Forward Citations = 543(Granted Patents)

Location History:

Longmont, CO (US) (2003 - 2009)
Supericer, CO (US) (2011)
Boudler, CO (US) (2014)
Boulder, CO (US) (2010 - 2024)
Lafayette, CO (US) (2014 - 2024)

Company Filing History:

Mirati Therapeutics, Inc.

patents

2 out of 2

Cogent Biosciences, Inc.

patents

4. 1 out of 12,157

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12351581 - Compounds for FGFR inhibition (2025-07-08),

2. 12281122 - PI3K inhibitors (2025-04-21),

3. 12187721 - Protein tyrosine phosphatase inhibitors (2025-01-07),

4. 11964989 - KRas G12D inhibitors (2024-04-23),

5. 11884664 - Protein tyrosine phosphatase inhibitors (2024-01-30),

6. 11634417 - Protein tyrosine phosphatase inhibitors (2023-04-25),

7. 11453683 - KRas G12D inhibitors (2022-09-27),

8. 10689377 - KRas G12C inhibitors (2020-06-23),

9. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2020-06-02),

10. 10633381 - KRas G12C inhibitors (2020-04-28),

11. 10125134 - KRas G12C inhibitors (2018-11-13),

12. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

13. 9174981 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2015-11-03),

14. 8865726 - Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors (2014-10-21),

15. 8841455 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors (2014-09-23),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'm pleased to present an article on inventor Martha E Rodriguez for idiyas.com.

Title: Unveiling the Inventive Journey of Martha E Rodriguez

Introduction:

Martha E Rodriguez, a brilliant inventor hailing from Boulder, CO (US), has made significant contributions to the field of pharmaceuticals with her innovative patents and groundbreaking research.

Latest Patents:

Rodriguez's latest patents revolve around KRas G12D inhibitors, compounds designed to inhibit the activity of KRas G12D, particularly focusing on treating cancer. Additionally, she has developed Protein Tyrosine Phosphatase inhibitors for the treatment of hyperproliferative diseases, showcasing her versatility in the medical realm.

Career Highlights:

Having accumulated a remarkable total of 21 patents, Martha E Rodriguez has cemented her position as a prolific inventor. Her tenure at esteemed companies like Array Biopharma Inc. and Mirati Therapeutics, Inc. has been marked by a relentless pursuit of innovative solutions to complex medical challenges.

Collaborations:

Throughout her career, Martha E Rodriguez has collaborated closely with industry experts such as Mark C Munson and James P Rizzi. These collaborations have fostered a culture of creativity and excellence, leading to the development of cutting-edge technologies that have the potential to revolutionize the pharmaceutical landscape.

Conclusion:

In conclusion, Martha E Rodriguez's trailblazing work in the realm of pharmaceutical innovations stands as a testament to her unwavering dedication to scientific advancement. Her patents not only exemplify her technical prowess but also underscore her commitment to improving the lives of patients worldwide through pioneering research and groundbreaking inventions.

This text is generated by artificial intelligence and may not be accurate.